| Identification | Back Directory | [Name]
IRL-2500 | [CAS]
169545-27-1 | [Synonyms]
IRL-2500
N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN
L-Tryptophan, 3-[1,1'-biphenyl]-4-yl-N-(3,5-dimethylbenzoyl)-N-methyl-D-alanyl- | [Molecular Formula]
C36H35N3O4 | [MDL Number]
MFCD00948945 | [MOL File]
169545-27-1.mol | [Molecular Weight]
573.68 |
| Chemical Properties | Back Directory | [Boiling point ]
893.7±65.0 °C(Predicted) | [density ]
1.246±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,Store in freezer, under -20°C | [solubility ]
Soluble to 100 mM in 1eq. NaOH | [form ]
Powder | [pka]
3.34±0.10(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
IRL 2500 is a potent endothelin ETB selective antagonist. | [Biological Activity]
Potent endothelin receptor antagonist; shows some selectivity for ET B receptors (IC 50 values are 1.3 and 94 nM for ET B and ET A receptors respectively). Inhibits ET B receptor-mediated blood pressure increase and renal vascular resistance in rats in vivo . | [in vivo]
IRL 2500 (intravenous injection;10 mg/kg) inhibits the initial transient decrease in mean arterial pressure (MAP) induced by the ETB-selective agonist IRL 1620 in rats, IRL 2500 also attenuates the IRL 1620-mediated increase in renal vascular resistance (RVR) in the anesthetized rat[1].
IRL 2500 (intravenous injection;10 mg/kg) pre-reatment significantly reduces the initial vasodepressor response to endothelin-1 (ET-1) and IRL 1620, however, it is not alters the secondary and sustained pressor response to these agonists[2]. | [IC 50]
ETB: 1.3 nM (IC50); ETA: 94 nM (IC50) | [storage]
Desiccate at RT |
|
| Company Name: |
|
| Tel: |
821-50328103-801 18930552037 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList13285/0.htm |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|